Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial

• DOI: 10.3109/0284186x.2012.752580
• Publication Date: 2012-12-18T12:58:13Z
• Authors: Dominik P. Modest; Ruediger P. Laube...; Sebastian Stintzing; Clemens Giessen; Christoph Schulz; Michael Haas; Ulrich Mansmann; Volker Heinemann
• Keywords: Adult; Male; Organoplatinum Compounds; Cetuximab; Middle Aged; Antibodies, Monoclonal, Humanized; Deoxycytidine; Disease-Free Survival; 3. Good health; Oxaliplatin; Drug Combinations; 03 medical and health sciences; 0302 clinical medicine; Proto-Oncogene Proteins; Antineoplastic Combined Chemotherapy Protocols; Mutation; Humans; Camptothecin; Female; Fluorouracil; Colorectal Neoplasms; Capecitabine; Aged

Purpose. This study investigated the impact of early tumor shrinkage (ETS) on progression-free- (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated within AIO KRK 0104 trial as first-line therapy. Moreover, correlations ETS clinical characteristics prognostic markers were evaluated. Patients methods. In total, 121 included into this analysis. cetuximab combined either CAPIRI or CAPOX. at six weeks was defined a relative change ≥ 20% sum longest diameters target lesions compared to baseline. Survival times between versus no-ETS. Results. observed 59% all KRAS wild-type tumors. these associated higher response rate (82% vs. 19%, p < 0.001). Also, PFS (8.9 4.7 months, 0.001) OS (31.6 15.8 = 0.005) significantly superior mutant mCRC neither had an effect nor OS. Cetuximab-induced skin toxicity correlated occurrence (p 0.002). Conclusion. tumors plus capecitabine-based chemotherapy is important predictor favorable outcome.